EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Scancell Holdings's enterprise value is €117.18 Mil.
Scancell Holdings's EBITDA for the trailing twelve months (TTM) ended in Oct. 2023 was €-11.33 Mil. Therefore, Scancell Holdings's EV-to-EBITDA for today is -10.34.
The historical rank and industry rank for Scancell Holdings's EV-to-EBITDA or its related term are showing as below:
FRA:SCP'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -11.18 Med: -7.37 Max: -6.1
Current: -10.15
During the past 13 years, the highest EV-to-EBITDA of Scancell Holdings was -6.10. The lowest was -11.18. And the median was -7.37.
FRA:SCP's EV-to-EBITDA is ranked worse than 100% of 459
companies
in the Biotechnology industry
Industry Median: 10.28
vs FRA:SCP: -10.15
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Scancell Holdings EV-to-EBITDA Historical Data
The historical data trend for Scancell Holdings's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Scancell Holdings's EV-to-EBITDA
For the Biotechnology subindustry, Scancell Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scancell Holdings's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Scancell Holdings's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Scancell Holdings's EV-to-EBITDA falls into.
Scancell Holdings's current Enterprise Value is €117.18 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Scancell Holdings's EBITDA for the trailing twelve months (TTM) ended in Oct. 2023 was €-11.33 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Scancell Holdings's PE Ratio for today is calculated as:
Scancell Holdings's share price for today is €0.096.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Scancell Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Oct. 2023 was €-0.014.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Scancell Holdings's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Scancell Holdings PLC is engaged in the discovery and development of novel vaccines for the treatment of cancer. The company is exploiting the unrivalled potential of the immune system to seek out and destroy cancer using two proprietary immuno-oncology platforms: ImmunoBody and Moditope. Its potent innovative DNA-based ImmunoBody therapies generate ultra-high avidity T cell responses that target and eliminate cancerous tumors. Its Moditope platform technology overcomes the immune suppression induced by tumors themselves, allowing activated T cells to seek out and kill tumor cells that would otherwise be hidden from the immune system.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:SCP has been successfully added to your 